A combination of PSA density, MRI, and PSMA PET findings identified a small subgroup with adverse pathology, supporting further study of biopsy-sparing pathways.
The approval is based on phase 3 PSMAddition results showing reduced risk of disease progression or death with Pluvicto plus standard of care compared with standard of care alone, according to Novartis.
An analysis of more than 57,000 women found lower reported rates of recurrent urinary tract infection among vegetarians and vegans, but experts cautioned that the findings could not establish causation.
KEYNOTE-B15/EV-304 demonstrated statistically significant improvements in event-free and overall survival with perioperative pembrolizumab plus enfortumab vedotin-ejfv compared with neoadjuvant gemcitabine plus cisplatin.
The phase 3 LITESPARK-022 trial compared adjuvant pembrolizumab plus belzutifan with pembrolizumab plus placebo following resection of clear-cell renal-cell carcinoma.
A large Epic Cosmos analysis linked vaginal estrogen prescribing with lower rates of sepsis, hospital admission, and death following recurrent urinary tract infection, but researchers cautioned that prescribing may also mark broader differences in care.